PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Gesamtlänge aller Episoden: 6 days 23 hours 16 minutes
Expanding Treatment Options in MET Exon 14-Skipping NSCLC: Clinical Insights From 2021 Virtual Congresses
Expanding Treatment Options in MET Exon 14-Skipping NSCLC: Clinical Insights From 2021 Virtual Congresses
Fortifying the Treatment of Prostate Cancer With AR-Targeted Therapy: Solidifying Clinical Guidance With Practical Evidence
Fortifying the Treatment of Prostate Cancer With AR-Targeted Therapy: Solidifying Clinical Guidance With Practical Evidence
A Case in Point: Navigating the Differential Diagnosis of aHUS in Clinical Practice
A Case in Point: Navigating the Differential Diagnosis of aHUS in Clinical Practice
What's on the Radio? 2021 Data Broadcast on Radioligands in Men With CRPC
What's on the Radio? 2021 Data Broadcast on Radioligands in Men With CRPC
Immunotherapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Which Antibodies for Which Patients?
Immunotherapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Which Antibodies for Which Patients?
Navigating the Evolving Therapeutic Landscape of RRMM: Expert Insights on the Latest Advances
Navigating the Evolving Therapeutic Landscape of RRMM: Expert Insights on the Latest Advances
Strategies to Maximize Long-Term Outcomes in Patients With Chronic Lymphocytic Leukemia (CLL)
Strategies to Maximize Long-Term Outcomes in Patients With Chronic Lymphocytic Leukemia (CLL)
Checkpoint Inhibitors for Advanced or Recurrent Endometrial Cancer: A New Standard of Care?
Checkpoint Inhibitors for Advanced or Recurrent Endometrial Cancer: A New Standard of Care?
Treating Anemia in Low- to Intermediate-Risk MDS: Translating the Latest Science into Patient Care
Treating Anemia in Low- to Intermediate-Risk MDS: Translating the Latest Science into Patient Care